Study Group: TOUCH Prescribing Program Experts: Neurologists(?)
Council Members in this Study Group: 57
Request a survey with this Study Group
Leading Experts in this Study Group
Daniel Wynn, MD
Director, Clinical Research
Consultants In Neurology Ltd.
Daniel Wynn, MD, FACN, FAASM, is a Director of Clinical Research at Consultants in Neurology in Chicago, Illinois. He has expertise in a wide variety of neurological illnesses and has served as a principal investigator in over 100 clinical trials in multiple sclerosis, Alzheimer's disease, stroke, chronic...
Neurologist
Medford Neurological Clinic, Inc.
Walter Carlini, MD, PhD, is a General Neurologist at Medford Neurological Clinic in Oregon. His clinical interests include stroke, epilepsy, migraine, dementia, movement disorders, and multiple sclerosis. Dr. Carlini has expertise in clinical neurophysiology and in the use of botulinum toxin injections...
President and Chief Executive Officer
AciesHealth
Mark Capriani, MBA, is the President and Chief Executive Officer of AciesHealth, a specialty pharmaceutical company in Pennsylvania. He has over 15 years of experience in pharmaceutical industry including biotech, branded and multi source pharmaceuticals, consumer products, device, and wound and burn...
Related Study Groups
GLG NewsSMAnalyses by this Study Group's Leading Experts(?)
Medications used for realistic indications and with clinically appropriate symptomatic targets are indicated and provide effectiveness that additional staff cannot offer. Decision making in health care is too often made by those who do not really provide clinical service but provide arm chair...
Extavia, Novartis' brand of interferon beta 1b, has been approved for the treatment of multiple sclerosis by the European Union. With FTY72, Fingolimod, Novartis has the eye on filing NDA by the end of 2009. While essentially identical to Bayer's Betaferon interferon beta 1b,...
The data on ABT-089 in adults has been released with positive results, whereas the adolescent/childhood trial is on-going for this novel compound for ADHD. The key difference is the potential to improve learning, not simply regain attention and lessen hyperactivity.
Copaxone has become the leading treatment for relapsing remitting MS in the US. The results of the PRECISE trial will likely add to TEVA's sales momentum and boost sales further.
Genentech will have more battles to fight in the future aside from Avastin. This medication appears extremely promising for the treatment of breast cancer, however, physicians are still mixed in their opinions about its place in the treatment of breast cancer.
Most Common Company Types:
- Academic Medical Center/Hospital or Clinic
- Office Based Private Practice or Clinic
- Non-Academic Community Hospital or Clinic
- Government/Military Hospital or Clinic
- Other Freestanding Healthcare Facility
- Pharmaceuticals Manufacturer
Most Common Job Types:
- Physician - Attending Physician
- Physician - Director
- Owner
- President
- Director
- Physician - Fellow
GLG's 750+ Clients Include:
global mutual funds
global banks
private equity firms